

**JOURNÉES SCIENTIFIQUES**  
Nantes Université

| 27 mai 2025

Participez au colloque :

# Des biomarqueurs aux thérapies innovantes dans les cancers à haut risque

*Inscrivez-vous jusqu'au 11 mai sur [js.univ-nantes.fr](https://js.univ-nantes.fr)*



COLLOQUE

N°16

## From Biomarkers to Innovative Therapies in High-Risk Cancers

8h30

Registration

8h45

### SESSION 1 : Next-generation therapies in oncology & hematology

Lecture: The saga of therapeutic antibody development in cancer

- Prof. Daniel Olive, professor of immunology, head of the Immunity and Cancer team, Cancer Research Center of Marseille

9h30

Engage them! Efficacy and mechanisms of action of bispecific antibodies in immunotherapies

- Prof. Cyrille Touzeau, hematologist, CHU Nantes
- Dr. Nils Giordano, postdoctoral researcher, CRCI<sup>2</sup>NA
- Dr. Catherine Pellat-Deceunynck, head of the Molecular Vulnerabilities of Tumor Escape in mature B-cell Malignancies team, CRCI<sup>2</sup>NA

10h05

Breaking tumour resistance with the rise of targeted therapies: from scientific innovation to medical application

- Prof. Benoît Tessoulin, hematologist, CHU Nantes
- Dr. David Chiron, head of the Molecular Vulnerabilities of Tumor Escape in mature B-cell Malignancies team, CRCI<sup>2</sup>NA

10h35

Break

10h50

CAR-T cells in brain tumours

- Dr. Claire Pecqueur, head of the Petry team, CRCI<sup>2</sup>NA
- Dr. Béatrice Clémenceau, research engineer in Manipulation of Lymphocytes for Immunotherapy team, CRCI<sup>2</sup>NA

11h20

### SESSION 2: Theranostics & targeted radionuclide therapies

Shaping the future of glioblastoma treatment: locoregional At-211 radiotherapy targeting Syndecan-1 leads durable remission & immune memory

- Dr. Emmanuel Garcion, head of the Innovative local alternatives in the medical treatment of glioblastoma team, CRCI<sup>2</sup>NA

11h35

Prospects for radiotheranostics in prostate cancer

- Dr. Clément Bailly, nuclear physician, CHU Nantes
- Prof. Stéphane Supiot, radiation oncologist, ICO
- Prof. Jérôme Rigaud, head of the urology department, CHU Nantes

12h15

Targeting CXCR4 in hematological diseases

- Prof. Caroline Bodet-Milin, nuclear physician, CHU Nantes

12h30

LUNCH

14h00

Lecture: Radioligand therapy and breast cancer: challenges and new horizons

- Prof. Désirée Deandreis, chief of the nuclear medicine division, Institut Gustave Roussy

14h40

### SESSION 3: Imaging & AI-driven biomarker discovery

**Interest of machine learning in PET for hematologic malignancies: from early developments to today**

- Dr. Thomas Carlier, medical physicist in nuclear medicine, CHU de Nantes
- Oriane Thierry, PhD student LS2N

15h10

### Using predictive models in radiotherapy: towards personalised medicine

- Dr. Tanguy Perennec, radiation oncologist, head of artificial intelligence unit, ICO

15h30

*Break*

15h45

### SESSION 4: Biomarkers & therapy response: new Insights in oncology & hematology

**FLT3-Ligand and IL-6: impact on acute leukemia management**

- Prof. Joëlle Gaschet, nuclear oncology team, CRCI<sup>2</sup>NA, Nantes Université
- Dr. Pierre Peterlin, hematologist, CHU Nantes

16h15

### Epigenetic/Epitranscriptomic biomarkers in lung cancer therapy

- Dr. Judith Raimbourg, medical oncologist, ICO
- Dr. Pierre François Cartron, researcher in Stress Adaptation and Tumor Escape team, CRCI<sup>2</sup>NA / ICO

16h45

**EV-Score as a biomarker: exploration of plasma extracellular vesicles from HR+ metastatic breast cancer patients under CDK4/6 inhibitors treatment**

- Prof. Jean-Sébastien Frenel, medical oncologist, ICO
- Dr. Laetitia Guével, Signaling in Oncogenesis, Angiogenesis and Permeability team, CRCI<sup>2</sup>NA, Nantes Université

17h15

**End of the conference**